Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/19934793http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/19934793http://www.w3.org/2000/01/rdf-schema#comment"

Introduction

The prodrug, clopidogrel, plays an important role in the prevention of thrombotic events in patients undergoing coronary stenting. However, a substantial number of atherothrombotic events still occur, which can partially be explained by heightened residual platelet reactivity. Several studies report that the genetic variation in CYP2C19 (*2) is associated with an impaired response to clopidogrel.

Objectives

To evaluate the effect of genetic variants affecting clopidogrel's absorption (ABCB1 C1236T, G2677T/A, C3435T), metabolism (CYP2C9*2, *3, CYP2C19*3, CYP3A4*1B, and CYP3A5*3), and pharmacodynamics (P2Y1 A1622G) on top of the influence of CYP2C19*2 on platelet reactivity in patients undergoing elective coronary stenting on dual antiplatelet therapy.

Methods

Platelet function was assessed by light transmittance aggregometry and VerifyNow P2Y12 assay in 428 consecutive patients. Patients were either on chronic clopidogrel maintenance therapy (75 mg/day for > or =5 days before the intervention) or received a 300 mg clopidogrel loading dose (1-5 days before the intervention, followed by 75 mg/day). Linear and logistic regressions were used to assess the associations between genetic variants and platelet reactivity and poor responder status.

Results

In both the treatment groups, CYP2C19*2-carriage was associated with higher platelet reactivity (P<0.002) and poor responder status; 75 mg group: adjusted odds ratio (ORadj): 3.8, 95% confidence interval (CI): 2.0-7.2, 300 mg group: ORadj: 4.1, 95% CI: 1.6-10.4. In the 300 mg group, CYP2C9*3-carriage was associated with higher platelet reactivity (P<0.05) and poor responder status (ORadj: 11.1, 95% CI: 1.6-78.8, P=0.016).

Conclusion

Besides CYP2C19*2, the variant allele CYP2C9*3 plays an important role in the response to clopidogrel in patients on dual antiplatelet therapy undergoing coronary stenting."xsd:string
http://purl.uniprot.org/citations/19934793http://purl.org/dc/terms/identifier"doi:10.1097/fpc.0b013e328333dafe"xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/author"de Boer A."xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/author"Ruven H.J."xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/author"Klungel O.H."xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/author"Deneer V.H."xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/author"Bouman H.J."xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/author"Breet N.J."xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/author"Hackeng C.M."xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/author"Harmsze A."xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/author"Ten Berg J.M."xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/author"Tjoeng M.M."xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/author"van Werkum J.W."xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/date"2010"xsd:gYear
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/name"Pharmacogenet Genomics"xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/pages"18-25"xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/title"Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation."xsd:string
http://purl.uniprot.org/citations/19934793http://purl.uniprot.org/core/volume"20"xsd:string
http://purl.uniprot.org/citations/19934793http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/19934793
http://purl.uniprot.org/citations/19934793http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/19934793
http://purl.uniprot.org/uniprot/#_F4ZUY5-mappedCitation-19934793http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19934793
http://purl.uniprot.org/uniprot/#_A0A2D1BLU4-mappedCitation-19934793http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19934793
http://purl.uniprot.org/uniprot/#_A0A2D1BPP2-mappedCitation-19934793http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19934793
http://purl.uniprot.org/uniprot/#_A0A2D1BPV8-mappedCitation-19934793http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/19934793
▶